M
Marco Spada
Researcher at University of Turin
Publications - 102
Citations - 2712
Marco Spada is an academic researcher from University of Turin. The author has contributed to research in topics: Fabry disease & Tetrahydrobiopterin. The author has an hindex of 21, co-authored 102 publications receiving 2227 citations. Previous affiliations of Marco Spada include Boston Children's Hospital & ISMETT.
Papers
More filters
Journal ArticleDOI
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Marco Spada,Severo Pagliardini,Makiko Yasuda,Turgut Tukel,Geetha Thiagarajan,Hitoshi Sakuraba,Alberto Ponzone,Robert J. Desnick +7 more
TL;DR: The results suggest that the later-onset phenotype of Fabry disease is underdiagnosed among males with cardiac, cerebrovascular, and/or renal disease and raises ethical issues related to when screening should be performed--in the neonatal period or at early maturity, perhaps in conjunction with screening for other treatable adult-ONSet disorders.
Journal ArticleDOI
Clinical outcome of long-term management of patients with vitamin B12-unresponsive methylmalonic acidemia.
S.B. van der Meer,F. Poggi,Marco Spada,Jean-Paul Bonnefont,Hélène Ogier,Philippe Hubert,E. Depondt,D. Rapoport,D. Rabier,C. Charpentier,P. Parvy,J. Bardet,P. Kamoun,J. M. Saudubray +13 more
TL;DR: Almost all the patients, especially those with early onset, had some degree of neurologic impairment and mental retardation, and many patients were at less than 2 SD for weight or height or both, in contrast, the neurologic and mental status of the late-onset patients was frequently normal, and their weight and height were more often within normal limits.
Journal ArticleDOI
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.
Dominique P. Germain,Perry M. Elliott,Bruno Falissard,Victor Fomin,Max J. Hilz,Ana Jovanovic,Ilkka Kantola,Aleš Linhart,Renzo Mignani,Mehdi Namdar,Albina Nowak,João Paulo Oliveira,Maurizio Pieroni,Miguel Viana-Baptista,Christoph Wanner,Marco Spada +15 more
TL;DR: A comprehensive systematic literature review of all original articles on Enzyme Replacement Therapy (ERT) in the treatment of Fabry disease published up until January 2017 is presented in adult male patients.
Journal ArticleDOI
European expert consensus statement on therapeutic goals in Fabry disease.
Christoph Wanner,Michael Arad,Ralf Baron,Alessandro P. Burlina,Perry M. Elliott,Ulla Feldt-Rasmussen,Victor Fomin,Dominique P. Germain,Derralynn Hughes,Ana Jovanovic,Ilkka Kantola,Aleš Linhart,Renzo Mignani,Lorenzo Monserrat,Mehdi Namdar,Albina Nowak,João Paulo Oliveira,Alberto Ortiz,Maurizio Pieroni,Marco Spada,Anna Tylki-Szymańska,Camilla Tøndel,Miguel Viana-Baptista,Frank Weidemann,Max J. Hilz +24 more
TL;DR: The consensus therapeutic goals and proposed patient management algorithm take into account the need for early disease-specific therapy to delay or slow the progression of disease as well as non-specific adjunctive therapies that prevent or treat the effects of organ damage on quality of life and long-term prognosis.
Journal ArticleDOI
Clinical outcome and long-term management of 17 patients with propionic acidaemia.
S.B. van der Meer,F. Poggi,Marco Spada,Jean-Paul Bonnefont,H. Ogier,Philippe Hubert,E. Depondt,D. Rapoport,D. Rabier,C. Charpentier,P. Parvy,J. Bardet,P. Kamoun,J. M. Saudubray +13 more
TL;DR: The prognosis for patients with propionic acidaemia appeared to be satisfactory in terms of survival and outcome characteristics such as neurological and mental development, and the authors feel that the prognosis and quality of life of these patients might be improved with liver transplantation or possibly somatic gene therapy in the future.